https://nt157inhibitor.com/sho....rt-term-experience-o
The occurrence (new-onset and recurrence) of uveitis ended up being reviewed retrospectively in like patients getting various TNF inhibitor therapies (adalimumab [ADA], infliximab [IFX], etanercept [ETN], and golimumab [GOL]) for the management of spondyloarthritis from 2005 to 2018. Kaplan-Meier analysis was carried out to calculate the cumulative event prices of uveitis during TNF inhibitor treatment, and a log-rank test was used to analyse differences when considering t
Gefällt mir
Kommentar
Teilen
